A Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in Subjects With Moderate to Severe Dry Eye Disease
Recruiting in Palo Alto (17 mi)
+3 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Kowa Research Institute, Inc.
Prior Safety Data
Trial Summary
What is the purpose of this trial?
The objective of the study is to assess the safety, efficacy, optimum dosage, and dosing regimen of K-161 in adult subjects with moderate to severe dry eye disease.
Research Team
Eligibility Criteria
Inclusion Criteria
Be at least 18 years of age at the time of informed consent visit.
Have a reported history of dry eye disease in both eyes and a history of eye drop use for dry eye symptoms.
Meet all inclusion criteria outlined in the clinical study protocol.
Treatment Details
Interventions
- K-161 (Unknown)
- Placebo (Vehicle) (Unknown)
Participant Groups
4Treatment groups
Experimental Treatment
Placebo Group
Group I: Group 3Experimental Treatment1 Intervention
K-161 Ophthalmic Solution Dose C.
Group II: Group 2Experimental Treatment1 Intervention
K-161 Ophthalmic Solution Dose B.
Group III: Group 1Experimental Treatment1 Intervention
K-161 Ophthalmic Solution Dose A.
Group IV: Group 4Placebo Group1 Intervention
Vehicle Solution Dose.
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Andover Eye AssociatesAndover, MA
Eye Research FoundationNewport Beach, CA
Central Maine Eye CareLewiston, ME
Total Eye Care, P.A.Memphis, TN
Loading ...
Who Is Running the Clinical Trial?
Kowa Research Institute, Inc.
Lead Sponsor
Trials
46
Patients Recruited
16,400+